ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Inhibikase Therapeutics Inc

Inhibikase Therapeutics Inc (IKT)

3,25
0,01
(0,31%)
Fermé 02 Janvier 10:00PM
3,25
0,00
(0,00%)
Après les heures de négociation: 1:00AM

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
3,25
Prix Achat
2,88
Prix Vente
3,37
Volume échangé
200 894
3,0403 Fourchette du Jour 3,49
1,12 Plage de 52 semaines 4,20
Cap du marché
Clôture Veille
3,24
Ouverture
3,36
Dernière Transaction
17
@
3.15
Dernière heure de transaction
Volume financier
US$ 647 684
VWAP
3,224
Volume moyen (3 m)
692 901
Actions en circulation
67 192 570
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-11,48
Bénéfice par action (BPA)
-0,28
Chiffre d'affairess
261k
Bénéfice net
-19,03M

À propos de Inhibikase Therapeutics Inc

Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to trea... Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Siège social
Wilmington, Delaware, USA
Fondé
-
Inhibikase Therapeutics Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker IKT. Le dernier cours de clôture d'Inhibikase Therapeutics était de US$3,24. Au cours de la dernière année, les actions de Inhibikase Therapeutics ont été négociées dans une fourchette de prix de US$ 1,12 à US$ 4,20.

Inhibikase Therapeutics compte actuellement 67 192 570 actions en circulation. La capitalisation boursière d'Inhibikase Therapeutics est de US$217,70 million. Inhibikase Therapeutics a un ratio cours/bénéfice (ratio PE) de -11.48.

IKT Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.3311.3013698632.923.252.9024897623.10588957CS
40.5520.37037037042.74.22.574578473.34902767CS
122.08177.7777777781.174.21.1466929012.04177131CS
262.01162.0967741941.244.21.123318822.01558678CS
521.92144.3609022561.334.21.122174992.07983175CS
156-5.51-62.8995433798.7610.80.791962413.45188873CS
260-60.77-94.923461418364.0270.80.792386079.58259375CS

IKT - Frequently Asked Questions (FAQ)

What is the current Inhibikase Therapeutics share price?
The current share price of Inhibikase Therapeutics is US$ 3,25
How many Inhibikase Therapeutics shares are in issue?
Inhibikase Therapeutics has 67 192 570 shares in issue
What is the market cap of Inhibikase Therapeutics?
The market capitalisation of Inhibikase Therapeutics is USD 217,7M
What is the 1 year trading range for Inhibikase Therapeutics share price?
Inhibikase Therapeutics has traded in the range of US$ 1,12 to US$ 4,20 during the past year
What is the PE ratio of Inhibikase Therapeutics?
The price to earnings ratio of Inhibikase Therapeutics is -11,48
What is the cash to sales ratio of Inhibikase Therapeutics?
The cash to sales ratio of Inhibikase Therapeutics is 833,33
What is the reporting currency for Inhibikase Therapeutics?
Inhibikase Therapeutics reports financial results in USD
What is the latest annual turnover for Inhibikase Therapeutics?
The latest annual turnover of Inhibikase Therapeutics is USD 261k
What is the latest annual profit for Inhibikase Therapeutics?
The latest annual profit of Inhibikase Therapeutics is USD -19,03M
What is the registered address of Inhibikase Therapeutics?
The registered address for Inhibikase Therapeutics is 1313 N MARKET ST STE 5100, SUITE 101, WILMINGTON, DELAWARE, 19801
What is the Inhibikase Therapeutics website address?
The website address for Inhibikase Therapeutics is www.inhibikase.com
Which industry sector does Inhibikase Therapeutics operate in?
Inhibikase Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BDMDBaird Medical Investment Holdings Ltd
US$ 7,6699
(630,47%)
89,74M
APMAptorum Group Ltd
US$ 2,799
(106,57%)
116,74M
COEPCoeptis Therapeutics Holdings Inc
US$ 5,44
(75,48%)
5,08M
VRMEVerifyMe Inc
US$ 1,332
(68,63%)
94,05M
VEEETwin Vee PowerCats Company
US$ 0,55
(53,59%)
5,62M
WATTEnergous Corporation
US$ 1,00
(-62,26%)
29,33M
SGMOSangamo Therapeutics Inc
US$ 1,02
(-56,41%)
44,56M
INTZIntrusion Inc
US$ 3,07
(-45,95%)
15,07M
KZIAKazia Therapeutics Ltd
US$ 1,78
(-42,58%)
708,99k
TOIIWOncology Institute Inc
US$ 0,0052
(-42,22%)
366,02k
SVMHSRIVARU Holding Ltd
US$ 0,0423
(26,65%)
794,74M
XTIAXTI Aerospace Inc
US$ 0,0422
(6,84%)
446,31M
EYENEyenovia Inc
US$ 0,1474
(30,10%)
412,83M
CRKNCrown Electrokinetics Corporation
US$ 0,146899
(5,91%)
402,05M
ONCOOnconetix Inc
US$ 0,6479
(48,26%)
270,47M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock